GSK's Jemperli (dostarlimab) just hit its primary goal in a mid-stage rectal cancer trial, with a "clinically significant" rate of patients showing no detectable cancer for one year or more after treatment. The Phase II AZUR-1 trial targeted tumors that cannot properly repair DNA damage, a subtype that accounts for 5%-10% of 730,000 annual global rectal cancer cases. Jemperli, already approved for certain endometrial cancers and a $1.1 billion seller in 2025, now...